Editorial: Minimally invasive therapies and molecular mechanisms related to recurrence in hepatobiliary and gastric cancers

Manqiu Kang, Wei Chen, Yuming Jiang, Changchang JiaFrontiers in Oncology 2023 · DOI · OpenAlex

Abstract

This research topic establishes a comprehensive platform for evaluating the clinical effectiveness and safety of minimally invasive therapies for liver, gallbladder, and gastrointestinal tumors. By integrating cutting-edge research, the study explores advanced non-invasive diagnostic methods for predicting tumor prognosis and unravels the molecular mechanisms associated with recurrence. Key findings highlight the potential of radiomics as a "virtual biopsy" and establish causal links between lipid metabolism and liver cancer risk, ultimately providing recommendations for advancing treatment and prognosis in these challenging malignancies.

Introduction

Hepatobiliary and gastric cancers remain among the most difficult malignancies to manage due to high recurrence rates and the anatomical complexity of the surgical sites. Patients often face a difficult trade-off between aggressive, invasive treatments and the risk of the cancer returning. This research addresses three primary gaps in current oncology: the prediction of post-surgical complications, the transition from invasive biopsies to non-invasive diagnostics, and the identification of systemic molecular drivers—such as obesity and lipid metabolism—that influence cancer development.

Methodological Innovations

The editorial synthesizes findings from several distinct methodological approaches:

  • Mendelian Randomization (MR) & Drug Target MR (DMR): Researchers utilized genetic variants as "natural experiments" to determine causal relationships between serum lipid markers and liver cancer incidence. This approach bypasses the confounding factors typical of standard observational studies.
  • Dual-Region CT Radiomics: This advanced image-processing technique extracts high-dimensional data from CT scans. By analyzing both the tumor and the surrounding tissue, researchers can predict the expression of specific proteins, such as FOXM1, without requiring a physical biopsy.
  • Retrospective Clinical Analysis: Historical patient data was analyzed to identify significant risk factors for surgical complications, such as anastomotic leakage following gastric resection.
  • Case Documentation: Detailed reporting on rare conditions, such as Primary Hepatic Neuroendocrine Tumors (PHNET), was used to establish standardized diagnostic protocols where large-scale trials are unfeasible.

Key Insights and Results

The "Virtual Biopsy" and Molecular Insights

A significant breakthrough in this research topic is the application of radiomics to predict FOXM1 expression in hepatocellular carcinoma (HCC). Because FOXM1 is a key driver of tumor progression, the ability to assess its expression through imaging allows for a non-invasive assessment of a tumor's molecular aggressiveness. This fusion of imaging and molecular detection represents a burgeoning domain with promising applications for patients who cannot undergo invasive testing due to their physical condition.

Lipid Metabolism and Cancer Prevention

Using Mendelian randomization, researchers established a causal link between individual serum lipid markers and the incidence of liver cancer. Specifically, the study suggests that LDL-c-lowering medications may mitigate the risk of liver cancer by reducing LDL-c levels. This provides a unique perspective on cancer prevention, suggesting that cardiovascular medications could serve a dual purpose in high-risk patients.

Improving Surgical Outcomes

In the context of gastric cancer, the research identified several significant predictive risk factors for anastomotic leakage, including low serum albumin, diabetes, laparoscopic surgery, and total/proximal gastrectomy. These findings support a shift toward better risk-stratification and the use of combined conservative and endoscopic treatments for managing post-surgical complications.

Limitations and Future Directions

While these pioneering reports offer significant innovation, the authors acknowledge that further validation is required. Future work must focus on:

  1. Validation: Testing radiomics and MR findings in larger, more diverse prospective cohorts to ensure clinical reliability.
  2. Standardization: Developing uniform protocols for radiomic features across different imaging hardware to ensure reproducibility.
  3. Clinical Integration: Determining how to best integrate these molecular and imaging insights into real-time surgical and oncological decision-making to further reduce recurrence rates.

In conclusion, the articles within this research topic emphasize the adoption of minimally invasive or non-invasive methods, offering increased convenience in clinical diagnosis while mitigating patient discomfort and providing viable remedies for complex clinical predicaments.

Summary updated

Abstract

This research aims to establish a platform for evaluating the clinical effectiveness and safety of minimally invasive therapies for liver, gallbladder, and gastrointestinal tumors. Additionally, it seeks to explore advanced non-invasive diagnostic methods for predicting tumor prognosis and unravel the molecular mechanisms associated with tumor recurrence in these areas. The study, enriched with cutting-edge research contributions, has successfully achieved its primary goals and formulated recommendations for advancing the treatment and prognosis of these tumors in the future. metabolism, the use of lipid-lowering medications, and liver cancer [3].Given the liver's pivotal role in lipid metabolism and the rising prevalence of obesity [4,5], understanding the connection between lipid metabolism, the utilization of lipid-lowering drugs, and the development of liver tumors becomes imperative. Employing Mendelian randomization analysis, the research establishes a causal relationship between individual serum lipid markers and the incidence of liver cancer. The study also employs drug target Mendelian randomization (DMR) analysis to assess the causal impact of LDL-c-lowering medications on the risk of liver cancer, suggesting that such drugs can mitigate the risk by reducing LDL-c levels.This study provides unique insights into predicting the occurrence of liver cancer and offers valuable recommendations for prevention.Additionally, Chen et al. conducted a significant study using dual-region CT radiomics to predict FOXM1 expression and prognosis in hepatocellular carcinoma (HCC) [6]. Integrating FOXM1 expression with radiomics offers a fresh perspective on non-invasive tumor characterization, implying its potential in providing molecular insights.Within this research topic, a case report by Tang et al. details two cases of primary hepatic neuroendocrine tumors (PHNET) [7]. The report aims to document the characteristics of this rare liver tumor, advance comprehension of the disease, enhance diagnostic precision, and explore standardized diagnostic and treatment approaches.Collectively, the articles within this research topic effectively align with its objectives and exhibit significant innovation. They emphasize the adoption of minimally invasive or non-invasive methods for the treatment and prognostication of liver, gallbladder, and gastrointestinal tumors, offering increased convenience in clinical diagnosis and treatment while mitigating patient discomfort. Pioneering reports, such as the use of Mendelian randomization analysis to establish the causal link between lipid-lowering drugs, LDL-c levels, and the development of liver cancer [3], serve as exemplary models for future research endeavors. The study on radiomics, a fusion of imaging and molecular detection, represents a burgeoning research domain with promising applications in the management of advanced tumors [6]. This research has the potential to provide optimal solutions for addressing the clinical challenges encountered by patients with advanced tumors who cannot undergo invasive testing due to their physical condition, thereby offering a viable remedy for this clinical predicament [8].
BibTeX
@inproceedings{kang2023editorial,
  author = {Manqiu Kang and Wei Chen and Yuming Jiang and Changchang Jia},
  title = {{Editorial: Minimally invasive therapies and molecular mechanisms related to recurrence in hepatobiliary and gastric cancers}},
  booktitle = {Frontiers in Oncology},
  year = {2023},
  doi = {10.3389/fonc.2023.1335049},
}
Figure